BCIQ Profiles

Company Profile Report

TPG, Vida back Asklepios in $235M round

TPG Capital and Vida Ventures have again teamed up to invest in a biotech's megaround, pouring a combined $225 million into gene therapy company Asklepios in exchange for a undisclosed minority stake. The company's founders and board members

Read the full 383 word article

How to gain access

Continue reading with a
two-week free trial.